

# EHA 2024 Congress

June 13–16, 2024  
Madrid, Spain



## TOP ABSTRACTS

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2024 Hybrid Congress, the ALL Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in ALL.

# EHA 2024: Top abstracts in ALL

June 13–16, 2024

Frontline and emerging therapies for ALL	
Abstract	Title
<b>S111</b> <a href="#">View</a>	Blinatumomab for first line treatment in intermediate and high risk Down Syndrome B-cell acute lymphoblastic leukaemia: Initial findings from the ALLTOGETHER1 DS TRIAL
<b>S112</b> <a href="#">View</a>	Blinatumomab as consolidation in a paediatric protocol leads to high rates of end-consolidation MRD negativity and excellent outcomes in AYA ALL – Final results of the ALLG ALL09 “SUBLIME” STUDY
<b>S113</b> <a href="#">View</a>	Blinatumomab added to prephase and consolidation therapy in adult B-ALL: A comparison of the consecutive HOVON-100 AND H-146 studies
<b>S115</b> <a href="#">View</a>	Ponatinib versus imatinib in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in the phase 3 PHALLCON trial: In depth responder analysis
<b>P397</b> <a href="#">View</a>	Augmented use of L-asparaginase markedly improves the treatment result of AYA ALL patients: Result of prospective MRD 2014 study conducted by Fukuoka Blood And Marrow Transplantation Group (FBMTG)
<b>P398</b> <a href="#">View</a>	Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the Phase 2 PONALFIL trial
<b>P400</b> <a href="#">View</a>	Busulfan plus cyclophosphamide vs. Total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia
<b>P407</b> <a href="#">View</a>	Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia/ lymphoblastic lymphoma (ALL/LBL): Post hoc analysis of adverse events of interest from AALL1931
<b>P409</b> <a href="#">View</a>	Blinatumomab induction therapy following reduced-dose chemotherapy in newly diagnosed adult Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: Multicentre, single arm, Phase 2 study
<b>P411</b> <a href="#">View</a>	A full pediatric regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia achieves excellent outcomes with acceptable toxicity
<b>P416</b> <a href="#">View</a>	Blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL): Safety run-in follow-up for the phase 3 GOLDEN GATE study.
<b>P427</b> <a href="#">View</a>	Combination of third generation TKI olverembatinib and chemotherapy or blinatumomab for new diagnosed adult Ph+ ALL patients
<b>P1740</b> <a href="#">View</a>	Improving outcome in elderly Philadelphia negative acute lymphoblastic leukemia: Feasibility and efficacy of an intensive PEG-asparaginase-based regimen

Treatments for relapsed/refractory ALL	
Abstract	Title
<b>S110</b> <a href="#">View</a>	WU-CART-007, an allogeneic CAR-T cell targeting CD7, is highly effective against relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL)
<b>S114</b> <a href="#">View</a>	Obecabtagene autoleucel in adult relapsed/refractory B-cell acute lymphoblastic leukemia: Survival and potential impact of CAR T-cell persistence and stem cell transplantation in the FELIX Study
<b>P395</b> <a href="#">View</a>	Subsequent allotransplant in adults with advanced acute lymphoblastic leukemia after CD19 CAR T-cell therapy: A multi-center randomized controlled trial
<b>P402</b> <a href="#">View</a>	Efficacy and tolerance of modified HyperCVAD, blinatumomab, and TKI, combination as a treatment for relapsed or refractory Ph+ B-cell acute lymphoblastic leukemia
<b>P429</b> <a href="#">View</a>	Five-year outcome of CD19 combined with CD22 CAR T-cell therapy in B-ALL patients relapsed after allo-transplantation

Biomarkers, prognosis, and biology	
Abstract	Title
<b>S116</b> <a href="#">View</a>	Early response refines end of induction measurable residual disease stratification in T-cell acute lymphoblastic leukaemia
<b>P403</b> <a href="#">View</a>	MRD monitoring in childhood Ph-positive acute lymphoblastic leukemia: Prognostic significance and correlation between multiparameter flow cytometry and RT-QPCR
<b>P419</b> <a href="#">View</a>	Impact of NGS MRD and clonal evolution on clinical prognosis in pediatric Ph+ ALL patients
<b>P368</b> <a href="#">View</a>	The genomic landscape of relapsed infant and childhood KNT2A-rearranged acute leukemia

Real-world outcomes	
Abstract	Title
<b>P413</b> <a href="#">View</a>	Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia with marrow blasts <5%, including patients (pts) with NGS MRD negative disease
<b>P424</b> <a href="#">View</a>	Real-world utilization of blinatumomab in adult and pediatric patients with acute lymphoblastic leukemia in France: Results from the ATHENA study



## EHA 2024

Follow us on X to keep up to date  
with the latest from the congress

**@ALL\_Hub\_**

**#EHA2024**

**View all @ALL\_Hub\_ tweets from #EHA2024**



Brought to you by

